Purified Membrane Proteins

MT1 Melatonin Receptor - Class A GPCR

CALIXAR’s MT1 (Melatonin receptor 1) helps you identify, develop, and test new molecules and therapeutic antibodies for CNS neuroprotection treatments for insomnia, circadian sleep disorders, depression, cardiovascular regulation, cancer, and neurodegenerative diseases.

MT1 Melatonin receptors 1 are powerful therapeutic candidates for insomnia, circadian sleep disorders, depression, cardiovascular regulation, cancer, and neurodegenerative diseases.

Purchase MT1 Melatonin Receptor class A GPCR

Our Melatonin receptor 1 (MT1) is a class A GPCR that modulates neuronal firing, arterial vasoconstriction, cell proliferation in cancer cells, and reproductive and metabolic functions.

Target name: Melatonin receptor type 1A (MT1)

Catalogue number: PP2

Class: GPCR Class A

Sequence: Full-length, wildtype sequence, with a N-terminus Strep tag II, 8xHis-tag, and TEV
protease cleavage site.

Affinity Tag​: Strepx2/His (both N-terminal)

Origin: Human (Homo sapiens)​

Theor. MW: 44,8kDa

Accession #: P48039 (UniProt)​

Shipment temperature: Dry Ice

Storage conditions: Store at -80°C​

Expression system: Sf9 insect cells (baculovirus)​

Purity: >90%

Purification: Metal Affinity Chromatography in presence of Sarkosyl/CHS

Activity: Confirmed by radiobinding assay and activation of Gi

Concentration​: Up to 5mg/ml

Sample buffer: 25mM Na2HPO4 pH 8.0, 150mM NaCl, 0.86%/0.18% Sarkosyl/CHS

Available quantity: From 10µg up to mg scale

€1,000.00 (10µg)

ships in 7 business days

First in market

CALIXAR is the first to produce native, wild-type, unmutated and untruncated targets.

Better discovery

Develop reliable and effective drugs and antibodies as they are not locked in any specific conformation.

Why choose us?

We apply a unique & custom-built program to give you an edge

Melatonin receptor 1 (MT1) is a class A GPCR that modulates neuronal firing, arterial vasoconstriction, cell proliferation in cancer cells, and reproductive and metabolic functions.  MT1 is a good therapeutic candidate for insomnia, circadian sleep disorders, depression, cardiovascular regulation, cancer, and neurodegenerative diseases.

CALIXAR’s MT1 Melatonin receptors aid in reliable fragment-based drug design (FBDD), structure-based drug discovery (SBDD) and antibody discovery against this specific target. 

Unlike Calixar’s MT1 Melatonin receptors, other alternative approaches have resulted in a Melatonin receptor that becomes mutated and truncated (96 amino-acids at the C-terminus). This truncation is unable to bind to its natural ligands. In addition, this mutated version becomes locked within an antagonist conformation.

As with all GPCRs, MT1 Melatonin receptors are unstable targets and inherently difficult to produce natively with conventional approaches. Traditionally, MT1 Melatonin receptors could only be locked in one specific conformation (e.g. antagonist) and were only ever developed in a solution that essentially cannot be pure, nor native (truncated, mutated), without PTMs, and consequently are unstable.

In contrast, CALIXAR’s MT1 Receptors are able to bind to agonists, antagonists, as well as allosteric modulators and preserve their structural and functional integrity. They are purified and stabilized to full length and wild-type (native) proteins.

CALIXAR’s MT1 Melatonin receptor 1 is the first native full-length and operative target on the market. Other existing MT1 targets are either mutated and or truncated. Our MT1 protein is produced in a eukaryotic arrangement with the precise post-translational adjustments (glycosylation).

CALIXAR’s MT1 Melatonin receptors are high-quality membrane proteins utilized in (bio)drug discovery projects and are adapted for use in pharmaceutical firms, biotechnology companies, as well as for academic teams that are committed to the life science fields.

  • Capacity to adapt the buffer condition
  • Antibodies (including nanobodies, scaffold proteins, aptamers)
  • Small molecules
  • 3D Structures (classical X-ray or XFEL, Cryo-EM, NMR)
  • Medicine discovery (Screening: HTS, FBDD, SBDD; Hit and lead validation)
  • Antibody discovery (Immunization and display technology)
  • Clinical stage (drug validation on reliable native MT1)

References

Molecular & Cellular Proteomics

Purification and identification of G protein-coupled receptor protein complexes under native conditions

Daulat AM. Et al. 2017 

Analytical Biochemistry

Novel systematic detergent screening method for membrane proteins solubilization.

Desuzinges Mandon E. et al. 2017

Membrane Protein Purchase

Please leave your contact information below, our sales team will get back to you as soon as possible to discuss the details with you.

Any question?

Give us a call : +33 481 076 460

Or leave us an email : contact(at)calixar.com